Page 17 - Alkermes News Today

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of Alkermes (NASDAQ:ALKS – Free Report) in a report released on Monday morning, Benzinga reports. They currently have a $33.00 target price on the stock. A number of other research analysts also recently issued reports on the stock. TheStreet raised shares of Alkermes from a […]

Environmental Protection & Sustainability at Alkermes

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor...

Rhenman & Partners Asset Management AB grew its position in Alkermes plc (NASDAQ:ALKS – Free Report) by 159.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 350,000 shares of the company’s stock after acquiring an additional 215,000 shares during the quarter. […]

Check out this week’s medical marketing news, people on the move and industry chatter.

By Josh Beckerman Mural Oncology shares were recently up 40%, to $5.31, in their second day on Nasdaq, following a wide price range Thursday after the...

Mural Oncology (NASDAQ:MURA) stock is rising higher on Friday after the company was separated from Alkermes (NASDAQ:ALKS). This separation went into effect on…

A year after Alkermes plc announced it would divide its oncology and neuroscience efforts into two separate businesses, the Dublin-based company spun out Mural Oncology plc with $275 million in funding and the lead solid tumor candidate nemvaleukin alfa. Shares of Mural (NASDAQ:MURA) will begin trading Nov. 16. “We’re very excited,” Mural’s CEO Caroline Loew told BioWorld. “We’ve got two major clinical datapoints in the next 18 months.”

Nagy will work within the health and wellness practice.

The spinoff between Mural and Alkermes created two pure-play companies.